NovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-020
Ewing, NJ, December 21, 2022– NovaRock Biotherapeutics Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared […]
Read MoreNovaRock Biotherapeutics Announces Exclusive License Agreement with CSPC to Develop and Commercialize NBL-012 in Select International Territories
Ewing, NJ, October 20, 2022– NovaRock Biotherapeutics Ltd., a clinical-stage biotechnology company focusing on the development of innovative antibody therapies […]
Read MoreNovaRock Biotherapeutics to Present at the 10th Annual Immuno-Oncology Summit 2022
Ewing, NJ, October 13, 2022 – NovaRock Biotherapeutics Ltd, a clinical-stage biotechnology company focusing on the development of innovative antibody […]
Read MoreNovaRock Biotherapeutics Presents a Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022
Ewing, NJ, April 10, 2022 – NovaRock Biotherapeutics Ltd, a clinical-stage biotechnology company focusing on the development of innovative antibody […]
Read MoreNovaRock Biotherapeutics Announces Exclusive LICENSE AGREEMENT and STRATEGIC PARTNERSHIP with Flame BioSciences
NovaRock granted Flame Biosciences exclusive license (excluding China, Hong Kong, Macau, and Taiwan) to co-develop, manufacture, and commercialize NBL-015, a […]
Read MoreNovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-015
Ewing, NJ, May 24, 2021– NovaRock Biotherapeutics Limited announced today that the U.S. Food and Drug Administration (FDA) has cleared […]
Read MoreNovaRock Receives Orphan-Drug Designation by the U.S. FDA for NBL-015 – a Fully Human Antibody Targeting Claudin-18.2 for the Treatment of Gastric Cancer
Ewing, NJ, April 7, 2021 – NovaRock Biotherapeutics Ltd announced today that their investigational new drug, NBL-015, a Claudin18.2 eADCC […]
Read MoreNovaRock Biotherapeutics Announces Two E-Posters to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2021
Ewing, NJ, March 30, 2021 – NovaRock Biotherapeutics Ltd, a clinical-stage biotechnology company focusing on the development of innovative antibody […]
Read MoreNovaRock Biotherapeutics Announces FDA Approval of IND Application for NBL-012 to Treat Inflammatory Diseases
Ewing, NJ, January 6, 2021 – NovaRock Biotherapeutics Ltd, announced today that the U.S. Food and Drug Administration (FDA) has […]
Read MoreNovaRock Receives Orphan-Drug Designation by the U.S. FDA for NBL-015 – a Fully Human Antibody Targeting Claudin-18.2 for the Treatment of Pancreatic Cancer
Ewing, NJ, December 3, 2020 – NovaRock Biotherapeutics Ltd, announced today that their investigational new drug, NBL-015, has been granted […]
Read More